Therapeutic Drug Monitoring (eBook, ePUB)

Newer Drugs and Biomarkers
Redaktion: Dasgupta Ph. D, Dabcc

• Format: ePub

Produktbeschreibung

Therapeutic Drug Monitoring 2nd Edition is an updated reference on TDM analytical techniques in diverse clinical settings.

This new edition reviews the exciting new developments in the area, including seven new chapters covering immunoassay design and applications, combined chromatographic techniques in therapeutic monitoring, drug monitoring in alternative specimens, pharmacogenomics of anticancer drugs, pharmacogenomics testing for patient management, selected antifungal agents, pharmacodynamic monitoring, and therapeutic drug monitoring of selected anticoagulants. All remaining chapters in the first edition were thoroughly revised and updated.

Therapeutic Drug Monitoring 2nd Edition is the ideal reference for clinical pathologists, pharmacologists, and toxicologists involved with TDM. Scientists working in diagnostic companies, developing reagents for monitoring therapeutic drugs will also find relevant information in this book.

• Includes new chapters covering antifungal, anticoagulant, and anticancer drugs monitoring
• Discusses limitations of current immunoassays, new and sophisticated chromatographic techniques, the clinical effectiveness of newer antiretroviral agents, anticonvulsants and antidepressants
• Provides full coverage of pharmacogenomics and personalized medicine, principles of pharmacokinetics and pharmacodynamics, and the application of biomarkers in TDM

---

Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.

Produktdetails

• Verlag: Elsevier Science & Techn.
• Seitenzahl: 550
• Erscheinungstermin: 26. April 2024
• Englisch
• ISBN-13: 9780443186509
• Artikelnr.: 70494764

Inhaltsangabe

Contents Contributors Preface 1. Introduction to therapeutic drug
monitoring: Frequently and less frequently monitored drugs Amitava Dasgupta
1. Introduction 2. Drugs that require therapeutic drug monitoring 3.
Benefits of therapeutic drug monitoring 4. Pathophysiological conditions
and other factors that affect drug concentrations 5. Therapeutic drug
monitoring of various drug class 6. Conclusions References 2. Effects of
preanalytical variables in therapeutic drug monitoring Janetta Bryksin and
Heather Stieglitz 1. Introduction 2. Lab-related variables 3.
Patient-specific variables 4. Conclusions References Further reading 3.
Analytical techniques used in therapeutic drug monitoring Michael C. Milone
1. Introduction 2. A general classification of analytical methods 3.
Understanding and minimizing measurement uncertainty in the clinical
laboratory 4. Immunoassays 5. Gas and liquid chromatography 6. Mass
spectrometry and LC-MS/MS application to TDM 7. Conclusions References 4.
Therapeutic drug monitoring using alternative specimens: Saliva and dried
blood spot Kenichi Tamama 1. Introduction 2. Free drug hypothesis 3. Remote
sampling for TDM 4. Oral fluid (saliva) 5. Saliva for TDM 6. Saliva
collection 7. Factors affecting the distribution of the analytes in DBS 8.
DBS with the precise volume deposition 9. Dried plasma spot 10. DBS for TDM
11. Specimen collection for DBS (and VAMS) 12. Laboratory analysis of
saliva and dried blood spot 13. Conclusions References 5. Clinical utility
of free-drug monitoring Florin Marcel Musteata 1. Introduction 2. Free
concentrations versus total concentrations 3. Applications and methods for
monitoring free drug concentrations 4. Alternative methods 5. Conclusions
References 6. Therapeutic drug monitoring of classical and newer
anticonvulsants Matthew Luke 1. Introduction 2. Pathophysiology of epilepsy
3. Antiepileptic drug monitoring 4. Indications for measuring a drug level
5. Therapeutic drug monitoring of classical AEDs 6. Newer anticonvulsants
7. Therapeutic monitoring of brivaracetam 8. Therapeutic monitoring of
cannabidiol 9. Therapeutic monitoring of cenobamate 10. Therapeutic
monitoring of clobazam 11. Therapeutic drug monitoring of eslicarbazepine
acetate 12. Therapeutic drug monitoring of felbamate 13. Monitoring of
fenfluramine 14. Monitoring of gabapentin 15. Therapeutic drug monitoring
of lacosamide 16. Therapeutic drug monitoring of lamotrigine 17.
Therapeutic drug monitoring of levetiracetam 18. Therapeutic drug
monitoring of oxcarbazepine 19. Therapeutic drug monitoring of perampanel
20. Therapeutic drug monitoring of pregabalin 21. Therapeutic drug
monitoring of rufinamide 22. Therapeutic drug monitoring of stiripentol 23.
Therapeutic drug monitoring of tiagabine 24. Therapeutic drug monitoring of
topiramate 25. Therapeutic drug monitoring of vigabatrin 26. Therapeutic
drug monitoring of zonisamide 27. Analytical methods for monitoring of AEDs
28. Conclusion References 7. Challenges in therapeutic drug monitoring of
digoxin and other antiarrhythmic drugs Amitava Dasgupta 1. Introduction 2.
Challenges in therapeutic drug monitoring of digoxin 3. Therapeutic drug
monitoring of other antiarrhythmic drugs 4. Chromatographic methods for
determining multiple antiarrhythmic drugs simultaneously 5. Conclusions
References 8. Guidelines for monitoring vancomycin, aminoglycosides, and
other antibiotics Amy L. Pyle-Eilola 1. Introduction 2. Vancomycin 3.
Aminoglycosides 4. Therapeutic drug monitoring of beta-lactam antibiotics
5. Therapeutic drug monitoring sulfonamides and trimethoprim 6. Therapeutic
drug monitoring of chloramphenicol and tetracycline 7. Therapeutic drug
monitoring of quinolones 8. Therapeutic drug monitoring of macrolides 9.
Therapeutic drug monitoring of antimycobacterial agents 10. Conclusions
References 9. Challenges in therapeutic drug monitoring of classical
tricyclic and newer antidepressants: analytical and pharmacogenetics
considerations Uttam Garg and Angela Ferguson 1. Introduction 2. Tricyclic
antidepressants 3. Newer antidepressants 4. Pharmacogenetic considerations
in TDM of antidepressants 5. Conclusions References 10. Antiretroviral drug
therapeutic drug monitoring for the management of human immunodeficiency
infection Patrick D. DeArmond and Dustin R. Bunch Abbreviations 1.
Introduction 2. Role of therapeutic drug monitoring 3. TDM instrumentation
and matrices of antiretroviral drugs 4. TDM of antiretroviral drugs by
classes 5. Challenges in practical application of TDM in managing patients
with HIV 6. Conclusion References 11. Therapeutic drug monitoring of
selected antifungal agents Matthew D. Krasowski 1. Introduction 2. Overview
of therapeutic drug monitoring of antifungal drugs 3. Analytical methods to
support TDM of antifungal drugs 4. Specific antifungal drugs 5. Conclusions
References 12. Therapeutic drug monitoring of selected direct oral
anticoagulants Emmanuel J. Favaloro and Robert C. Gosselin 1. Introduction
2. DOAC: Pharmacokinetic, pharmacodynamics, clinical indications, and
dosing 3. DOAC measurementsdoverview 4. Conclusion References 13. Drug
testing in pain management Bridgit O. Crews and Amadeo J. Pesce 1.
Introduction 2. Utility and cost of drug testing in pain management 3.
Substance abuse and addiction medicine 4. Drug testing approaches 5. Drug
testing menu 6. Results reporting 7. Testing frequency 8. Specimen types
and alternative specimens 9. Specimen collection and testing workflow 10.
Analytical approaches 11. Specific analytes and interpretation 12.
Stimulants 13. Novel psychoactive substances 14. Pharmacogenomics 15.
Conclusions References Further reading 14. An introduction to personalized
medicine Joshua Bornhorst 1. Introduction 2. Overview of classical sequence
variation profiling techniques 3. Recent molecular profiling technologies
4. Select example biomarkers in pharmacogenomics 5. Translational
approaches associated with pharmacogenomics and personalized medicine 6.
Conclusions References Further reading 15. Genomic technology advances and
the promise for precision medicine Jacopo Umberto Verga, Adam Lloyd, Arthur
Sarron, and Gary Hardiman 1. Introduction 2. DNA microarrays 3. Sequencing
technologies 4. Pharmacogenetic testing and healthcare 5. Systems medicine
6. Disease diagnosis 7. Drug discovery 8. Precision medicine 9. Challenges
in machine learning for systems medicine 10. Conclusion 11. Future
prospects References 16. Pharmacogenomics and warfarin therapy Jennifer
Martin 1. Introduction 2. The potential of pharmacogenetics for warfarin 3.
Pharmacology 4. Nongenetic factors affecting warfarin dosing 5. Clinical
relevance 6. Cost-effectiveness of pharmacogenomics testing in warfarin
therapy 7. Conclusion References 17. Drug hypersensitivity linked to
genetic variations of human leukocyte antigen Debleena Guin and Ritushree
Kukreti 1. Introduction 2. HLA: Molecular structure, genomic organization,
polymorphism, and nomenclature 3. Repositories related to HLA alleles and
associated ADRs 4. HLA alleles and their association with drug-induced ADRs
5. Steven Johns syndrome/toxic epidermal necrolysis (SJS/TEN) 6.
Morbilliform drug eruption 7. Drug reaction with eosinophilia and systemic
symptoms DRESS 8. Drug-induced liver injury 9. Clinical recommendations for
HLA genotyping 10. Conclusions Acknowledgment References 18. Therapeutic
drug monitoring of selected anticancer drugs: pharmacogenomics issues
Michael C. Milone 1. Introduction 2. Traditional therapeutic drug
monitoring for anticancer drugs 3. Newer approaches to personalized dosing
and treatment with anticancer agents: pharmacogenetics 4. Pharmacogenetic
considerations for specific anti-cancer agents 5. Conclusions References
19. Consequences of differences in bio-analytical assays for the precision
monitoring of immunosuppressive drugs Serge Cremers and Alex Lyashchenko 1.
Introduction 2. Immunosuppressive drugs and their metabolites 3. Sample
matrix 4. Various analytical techniques for measuring immunosuppressants 5.
Stability 6. Proficiency testing and comparison studies 7. Interassay
differencesdare they relevant? 8. Conclusions References 20. Donor-derived
cell-free DNA as a marker of graft injury after solid organ transplantation
Michael Oellerich, Klemens Budde, Kirsten Bornemann-Kolatzki, Karen
Sherwood, Bilgin Osmanodja, Michael Melter, Julia Beck, Ekkehard Schütz,
Paul Keown, and Philip D. Walson 1. Introduction 2. Causes of chronic
allograft dysfunction 3. Need for biomarkers 4. Value of conventional TDM
5. Biomarkers for immune monitoring as supplement to TDM 6. Molecular
methods: Biopsy and cellular approaches 7. Conclusions References 21.
Pharmacodynamic monitoring as an integral part of therapeutic drug
monitoring Loralie J. Langman and Paul J. Jannetto 1. Introduction 2. Drug
concentrations 3. Pharmacodynamic monitoring 4. Physiological biomarkers 5.
Laboratory biomarkers 6. Drug-specific and nonspecific PD biomarkers 7.
Summary References 22. Role of therapeutic drug monitoring to identify
clinically significant drug-herbal supplement interaction Sergei Likhodii,
Alex C. Chin, and Leland B. Baskin 1. Introduction 2. Herbedrug interaction
mechanisms 3. Impact of herb supplements and herbedrug interactions in
clinical practice 4. Contamination of herbal supplements 5. Analytical
interferences caused by some herbal supplements 6. Conclusions References
Index